The effects of rituximab treatment during pregnancy on a neonate.
A 35-year old woman developed Burkitt's lymphoma and was treated with rituximab and CHOP therapy early during pregnancy. Monitoring of rituximab concentrations and B-cell counts in the child revealed a transient complete B-cell depletion associated with high rituximab cord blood concentrations. B-cell recovery was fast, showing a regular immunophenotype without loss of CD20 antigen, no functional deficits and adequate vaccination IgG titers.
Friedrichs
Birte
B
Tiemann
Markus
M
Salwender
Hans
H
Verpoort
Karl
K
Wenger
Michael K
MK
Schmitz
Norbert
N
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000097:blood; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002051:Burkitt Lymphoma / Q000097:blood / Q000188:drug therapy; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005312:Fetal Blood / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn / Q000097:blood*; D011241:Prednisone / Q000008:administration & dosage; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000097:blood*; D000069283:Rituximab; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone